Background The 3 fuoroquinolone (FQ) antibiotics -ciprofoxacin, levofoxacin, and moxifoxacin -are commonly administered to oncology patients. Although these oral antibiotics are approved by the US Food and Drug Administration (FDA) for treatment of urinary tract infections, acute bacterial sinusitis, or bacterial infection in patients with chronic obstructive pulmonary disease, they are commonly prescribed off-label to neutropenic cancer patients for the prevention and treatment of infections associated with febrile neutropenia. New serious FQ-associated safety concerns have been identifed through novel collaborations between FQtreated persons who have developed long-term neuropsychiatric (NP) toxicity, pharmacovigilance experts, and basic scientists. Objective To conduct basic science and clinical investigations of a newly identifed adverse drug reaction, termed FQassociated disability. Methods 5 groups of C57BL/6 mice receiving the antibiotic ciprofoxacin in 10-mg increments (10 mg/kg-50 mg/kg) and 1 group of control mice were evaluated. The Southern Network on Adverse Reactions (SONAR) and a social network of FQ-treated persons with long-term NP toxicity (the Floxed Network) conducted a web-based survey. The clinical toxicity manifestations reported by 94 respondents to the web-based survey of persons who had received 1 or more doses of an FQ prescribed for any indication (generally at FDAapproved dosages) and who subsequently experienced possible adverse drug reactions were compared with adverse event information included on the product label for levofoxacin and with FQ-associated adverse events reported to the FDA's MedWatch program. Results Mice treated with ciprofoxacin had lower grip strengths, reduced balance, and depressive behavior compared with the controls. For the survey, 93 of 94 respondents reported FQ-associated events including anxiety, depression, insomnia, panic attacks, clouded thinking, depersonalization, suicidal thoughts, psychosis, nightmares, and impaired memory beginning within days of FQ initiation or days to months of FQ discontinuation. The FDA Adverse Event Reporting System (FAERS) included 210,705 adverse events and 2,991 fatalities for FQs. Levofoxacin and ciprofoxacin toxicities were neurologic (30% and 26%, respectively), tendon damage (8% and 6%), and psychiatric (10% and 2%). In 2013, an FDA safety review reported that FQs affect mammalian topoisomerase II, especially in mitochondria. In 2013 and 2014, SONAR fled citizen petitions requesting black box revisions identifying neuropsychiatric toxicities and mitochrondrial toxicity as serious levofoxacin-associated adverse drug reactions. In 2015, FDA advisors recommended that FQ product labels be revised to include information about this newly identifed disability syndrome termed "FQ-associated disability" (FQAD). Limitations Basic science studies evaluated NP toxicity for only 1 FQ, ciprofoxacin. Conclusion Pharmacovigilance investigators, a social network, and basic scientists can collaborate on pharmacovigilance investigations. Revised product labels describing a new serious adverse drug reaction, levofoxacin-associated long-term disability, as recommended by an FDA advisory committee, are advised.
T he fuoroquinolones (FQs) ciprofoxacin, levofoxacin, and mofoxacin are oral antibiotics often administered to cancer patients for prophylaxis and/or treatment of bacterial infections resulting from chemotherapy-associated febrile neutropenia. Te US Food and Drug Administration (FDA) approvals support FQ treatment of a range of infections such as pneumonias, acute bacterial sinusitis, exacerbation of chronic bronchitis, skin infections, chronic bacterial prostatitis, urinary tract infections, acute pyelonephritis, and inhalational anthrax. 1, 2 Levofoxacin, ciprofoxacin, and moxifoxacin are currently the only FQs marketed in the United States. Newer FQs are more potent and active across a broader spectrum, have improved pharmacokinetic properties, and, if they receive FDA approval, are likely to be prescribed in place of levofoxacin, ciprofoxacin, or moxifoxacin to cancer patients for prevention or treatment of bacterial infections. 3 FQs are associated with a range of toxicities. As is the case with many other medications administered to cancer patients, some FQ toxicities have not been fully characterized even though they have been in use since 1987, when ciprofoxacin 4 was approved for use in the United States. Tree FDA-approved FQs, temarfoxacin, trovofoxacin, gatifoxacin, were withdrawn from the market in 1992, 1999, and 2006, respectively, after the FDA received spontaneous reports of severe toxicities, including hepatotoxicity. 2, 3 FQ product labels currently include black box warnings for tendinitis, tendon rupture, and neurotoxicity (among myasthenia gravis patients). 1, 5 An important part of pharmacovigilance is to understand the mechanisms of toxic efects. Preclinical models can facilitate these assessments. Previous preclinical studies identifed FQ-associated abnormalities in the peripheral and central nervous systems. For example, in mice, sparfoxacin plays a role in hampering neuromuscular strength and inducing depressive behaviors after the administration of 25 mg/kg and 50 mg/kg of the drug. 6 Anxiogenic efects were also seen in mice that were administered gatifoxacin. 7 Only one animal study has evaluated FQ-associated neuropsychiatric (NP) toxicity using therapeutic dosages of ciprofoxa-cin. 8 Tat study, conducted in 30 rats, evaluated controls and rates that received doses of 20 mg/ kg or 50 mg/kg administered orally for 14 days. Evidence of ciprofoxacin-associated depression, anxiety, and abnormal locomotor activity and motor coordination at the 50-mg/kg dose was reported. Altered brain neurotransmitter levels and increased oxidative stress were identifed and thought to be the possible mechanisms of ciprofoxacin-associated neurotoxicity. 8
SONAR and the Floxed Network
Te Southern Network on Adverse Reactions (SONAR) is an independent pharmacovigilance program funded by a National Cancer Institute R01 grant, a SmartState grant from the Education Lottery State of South Carolina, and additional pilot grants. 4 Te network's principal investigator was contacted by individuals who had experienced long-term NP toxicity following use of an FQ and who had developed a social network of individuals with concerns over possible FQ drug toxicity (the Floxed Network). In a novel collaboration, SONAR, basic scientists, and the Floxed Network conducted studies to evaluate FQ-associated NP toxicity. A basic science study with C57/BL6 mice evaluated FQ-associated NP toxicity concerns raised initially by the Floxed Network. Another study, led by members of the Floxed Network, developed, conducted, and analyzed a web-based survey of persons who experienced possible FQ-associated toxicity. SONAR and the Floxed Network analyzed FQ-associated long-term NP toxicity in FDA Adverse Event Reports (FAERS), the Floxed Network survey, and the product label for levofoxacin. Te study received Institutional Review Board approval from the University of South Carolina.
Te mouse study
Animal studies play an important role in drug safety evaluation, particularly in investigating possible dose-toxicity efects. FQ-associated NP toxicity was investigated by exposing C57BL/6 mice to increasing dosages of ciprofoxacin, the FQ that has been on the market the longest and is the fourth most commonly prescribed antibiotic overall. 9 While ciprofoxaxin-associated NP toxicity has not been evaluated in experimental studies in humans,
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we investigated whether previous fndings of NP toxicity identifed in rats could be replicated in mice, and if toxicity occurred primarily at higher doses of ciprofoxacin. In this study, as in the prior study of ciprofoxcanassociated neurotoxicity in rats, anxiety levels of animals were assessed using elevated plus maze testing. 8 Tis test depends on behavioral inhibition associated with certain features (open elevated arms or closed arms, for example) of the test apparatus. 10
Methods

Basic science
Six-to eight-week-old C57BL/6 mice housed in a conventional animal room were treated with ciprofoxacin in the Animal Resource Facility at the University of South Carolina. Treatment and control mice were kept under a 12:12 hour light-dark cycle in a low-stress environment (22°C, 50% humidity, low noise) with access to food (Purina Chow) and water ad libitum. Tey were randomly assigned to 5 treatment groups (n = 10 each; receiving 10, 20, 30, 40, and 50 mg/kg of ciprofoxacin, respectively) and 1 control group of 10 mice receiving placebo. Each group had equal numbers of males and females. Ciprofoxacin (Bayer, West Haven, CT) was prepared in solution in deionized water in 10, 20, 30, 40, and 50 mg/ kg concentrations, based on previous FQ studies. 6 In all, 200 µl of each of the concentration's drug solutions or PBS (control group) was administered orally daily for 10 days. (Dosages of roughly 2-35 mg/kg are administered to humans; assuming standard dosages of 250 and 1,500 mg of ciprofoxacin daily, and human weights of 43 kg and 120 kg as examples ranging from light to heavy individuals. In humans, FDA-approved adult FQ dosages range from 250 mg once or twice a day for a duration of 3-60 days, depending on the infection). 5 Limb strength for mice in the treatment and control groups was measured using grip strength meters every second day over 10 days. Rotarod experiments for evaluation of locomotion and balance were performed every other day. We used an elevated plus maze (EPM) to measure the anxiogenic efects of ciprofoxacin, by comparing the time spent by mice in the maze's closed and open arms during 5 minutes. Locomotory behavior was analyzed by counting the total number of squares crossed by mice in 5 minutes on the EPM apparatus.
Mice in the treatment and control groups were euthanized with anesthesia (isofurane, Vedco) and cervical dislocation method, on the 11th experimentation day. Blood was obtained from the inferior vena cava, quadriceps muscles, and brain. Sections from quadriceps muscles and brain tissues were fxed in 10% formalin for immunohistochemistry. TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) assay and HMGB-1 (highmobility group binding protein-1) immunochemistry was performed on brain tissue slides to quantify apoptosis and necrosis.
Cellular oxygen consumption rates after ciprofoxacin treatment of C2C12 (mouse myoblasts) and HT-22 (mouse hippocampal neurons) cell lines were quantifed using the cell respirometer (Seahorse Biosciences). Cells were treated with 2.5, 5.0, 10, and 15 µg/ml of ciprofoxacin for 48 hours.
SigmaStat software (version 4.0 Systat Software, San Jose, CA) was used to evaluate diferences among experimental groups, using one-way and two-way analysis of variance (ANOVA) and Tukey post hoc tests. A P value of less than .05 was considered signifcant.
Clinical studies
Web-based survey. Cases were obtained with assistance of the Floxed Network. Respondents (N = 94) were asked to describe the NP events they experienced and to note whether they had reported the events to the FDA. A third question asked the respondents about physician responses to reports by patients of possible FQ toxicity.
FAERS review.
We submitted a Freedom of Information Act (FOIA) request for access to reports to the FDA from November 1, 1997 to July 21, 2015 for FQ-associated adverse events.
Results
Basic science
Grip strength values were highest for control mice during all days of experimentation except on day 0 and lowest for the treatment group that received the highest dose (50 mg/ kg) of ciprofoxacin ( Figure 1A ). Grip strength values were signifcantly lower for the 40 and 50 mg/kg ciprofoxacin treatment groups compared with the controls on all days of experimentation. Mice that received 30, 40, and 50 mg/kg ciprofoxacin showed signifcant decreases in numbers of successful rotations performed on the rotarod on all days of experimentation except day 0, compared with controls ( Figure 1B ). For the groups receiving 40 and 50 mg/kg ciprofoxacin, the number of successful rotations decreased signifcantly on day 10 compared with day 0.
Tere was a signifcant increase in the percentage of closed arm entries on the EPM in all treatment groups compared with controls, except for the 10 mg/kg ciprofoxacin group ( Figure 1C ). Te percentage of closed arm entries consistently increased with increasing ciprofoxacin dosage. Tere was signifcantly decreased locomotor activity on the open feld apparatus among all treatment groups compared with their control counterparts on days 5 and 10 ( Figure 1D ). Signifcant decreases in locomotor and exploratory behavior alterations occurred for the 10, 20, 30, and 40 mg/kg ciprofoxacin groups on day 10 compared with day 5 within the same group.
Brain cortex tissue showed signifcantly higher levels of apoptosis among all treatment groups compared with controls ( Figure 2 ). Immunohistochemical studies on brain tissues revealed signifcantly higher expression in levels of the HMGB-1 protein among ciprofoxacin-treated mice compared with controls ( Figure 3A -F and corresponded to ciprofoxacin dosage ( Figure 3G ).
Oxygen consumption rates for maximal respiration decreased from 1,000 pmoles/min/µg of protein in controls, compared with 300 pmoles/min/µg of protein in both C2C12 and HT-22 cells treated with 15 µg/ml (highest concentration) of ciprofoxacin (fgure not shown). Tere was a signifcant reduction in oxygen consumption rate for all dosages of ciprofoxacin except the 5 µg/ml treatment of C2C12 cells compared with controls.
Clinical study
Overall, 94 individuals responded to the Floxed Network web-based survey. Responses described a range of psychiatric efects (Table 1) , including anxiety (72%), depression (62%), insomnia (48%), panic attacks (37%), cognitive impairment (33%), depersonalization and/or derealization (29%), suicidal thoughts (24%), psychosis and/or hallucinations (22%), nightmares and/or abnormal dreams (21%), and impaired memory (21%). About half of the survey respondents (54%) had fled MedWatch reports with the FDA on the efects they experienced, and more than half reported that their medical providers were unaware that FQ toxicity might include the clinical events that the individual patients had reported to MedWatch ( Table 2) .
Te psychiatric adverse events identifed by Floxed ing the study for different treatment groups. C, Percentage changes in the closed arm entries from days 5-10 on the elevated plus maze for different treatment groups. D, Locomotor activity profle of mice depicted in dosage dependent manner. One-way and two-way repeated measure analysis of variance were used to calculate signifcant differences between: control and different ciprofoxacin treatment groups on same days of experiment, #P < .01 , *P < .03, **P < .04; between Day 0 and Day 10 measurements within individual ciprofoxacin treatment groups, €P < .01, $P < .05, @P < .03; and between Day 5 and Day 10 measurements within the individual ciprofoxacin treatment groups, ##P < .01, @P < .04, ζP < .03.
www.jcso-online.com Network survey respondents were compared with information provided on the levofoxacin product label in 3 locations (Sections 5, 6, and 17) related to adverse events (Table 3) . Several respondents reported NP toxicities that were not listed in the product label, including panic attacks (37% of respondents); brain fog and/or cognitive impairment (33%); depersonalization and/or derealization (29%); impaired memory (21%); emotional outbursts and/or mood swings (17%); agitation (9%); attention defcit and/or lack of concentration (9%); sensation of pending doom (7%); difculty reading and/or doing math (7%); mania and/or hyperactivity (6%); and rage and/or temper fares (5%). Te FDA received 210,7045 adverse event reports for marketed FQs between November 1, 1997 and July 28, 2015. For levofoxacin and ciprofoxacin, information was received for 24,777 and 22,488 patients, respectively; 98,710 and 100,865 adverse events; and 1,594 and 2,072 deaths. Te most commonly reported toxicities ( Figure 4 ) were neurologic (30% and 26%), tendon damage (8% and 6%), and psychiatric (10% and 2%).
Some levofoxacin NP adverse events reported to the FDA and included in the FAERS data are included on the levofoxacin product label, including insomnia, anxiety, depression, and confusion (Table 4 ). Other NP adverse events reported in FAERS are not included on the product label, including feeling abnormal, loss of consciousness, disorientation, agitation, delirium, depressed level of consciousness, Not one doctor thought the fuoroquinolones did this to me.
They totally ignored all my problems after being given levofoxacin… My doctors deny that these issues are connected to FQ antibiotics.
Mostly disbelief -I thought I was exaggerating things.
Ignored, dismissive, dismissed, [they] seemed angry with me.
It was all in my head.
They refused to believe my problems have anything to do with taking ciprofoxacin … Absolutely no admission from any physician that this could possibly be caused by FQs.
'We don't think this is from antibiotics at all.'
Dismissive. Refused to acknowledge fuoroquinolone toxicity …
Disbelief from all but one.
'We think she is depressed.' Seemed unconcerned.
I was advised to go to counseling.
'It should be out of my system.' a 56 respondents (60%) said they believed that the medical community was not aware of any fuoroquinolone toxicity and/or did not believe the individual's new onset medical issues could be related to a fuoroquinolone. b 38 respondents (40%) said that at least 1 physician was aware of some fuoroquinolone toxicities and/or believed the individual's new onset medical issues could be related to a fuoroquinolone.
Original Report psychotic disorder, amnesia, coma, disturbance in attention, panic attack, memory impairments, nervousness, and restlessness. In addition, according to FAERS data on levofoxacin, reports that contain descriptions of suicide ideation or suicide attempt were reported almost twice as frequently during 2006-2015, compared with 2002-2005. Tree sections on the levofoxacin product label report on adverse events: Section 5 (Warnings and Precautions); Section 6 (Adverse Reactions); and Section 17 (Patient Counseling Information). 1 Reporting of psychiatric toxicities is inconsistent among the 3 sections.
In Section 5 (Warnings and Precautions), there is no subsection containing the term psychiatric. A small number of psychiatric adverse events are listed under the heading, 5.6 (Central Nervous System Efects), and include: "FQs may cause central nervous system stimulation which may lead to tremors, restlessness, anxiety, lightheadedness, confusion, hallucinations, paranoia, depression, nightmares, insomnia, and, rarely, suicidal thoughts or acts." 1[p.15] In Section 6, there is no subsection containing the term psychiatric. Section 6.1 (Serious and Otherwise Important Adverse Reactions) refers to Section 5 (Warnings and Precautions). In Section 6.3 (Postmarketing Reports of Adverse Drug Reactions), "psychosis, paranoia, and iso- lated reports of suicide attempt and suicidal ideation" are listed under Psychiatric Disorders.
In Section 17 (Patient Counseling Information), there are no references to psychiatric adverse events. In Section 17.6 (Medication Guide) psychiatric adverse events are not listed under a heading that uses the term psychiatric. Tere are NP adverse events mixed with nonpsychiatric adverse events under the heading, Central Nervous System Efects. Tese include "hallucinations, restlessness, anxiety, confusion, depression, insomnia, nightmares, paranoia, and suicidal thoughts or actions". 1[pp. 66-67] 
Discussion
Tis collaboration among SONAR, basic scientists, and the Floxed Network has identifed FQ-associated psychiatric toxicities as toxicities that are not well described in current product labels. In interpreting our fndings, several factors should be considered.
Research for evaluating potentially serious adverse drug reactions in the oncology feld is limited. When an oncology patient develops toxicity, the changes are usually attributed to the cancer or chemotherapy and rarely to supportive agents or immunologic agents. Such is the case with venous thromboembolism that is associated with erythropoietin and darbepoetin, for example. 11, 12 With respect to NP toxicity, a decade elapsed before rituximab was associated with progressive multifocal leucoencephalopathy (PML). 13 More recently, PML was also identifed among cancer patients being treated with brentuximab vedotin. 14 Tese pharmacovigilance initiatives conducted by SONAR have been funded mainly by peer-reviewed grants. 4 It is unlikely that similar eforts can be widely replicated because of funding limitations. SONAR is the only joint state-funded and National Cancer Institute-funded pharmacovigilance program.
Basic science studies evaluated the efects of human recommended dosages of ciprofoxacin at behavioral, cellular, and molecular levels in mouse models. Results from measurements of grip strength and balance support studies linking FQs to reduced physical strength and coordination in mice, 6, 7, 15, 16 indicating potential neurotoxicity caused by ciprofoxacin administration. Moreover, altered behavioral responses pertaining to anxiety and depression as measured by EPM and open-feld experiments indicate psychotoxic potential of ciprofoxacin. [17] [18] [19] [20] Te fndings parallel reports of FQ-associated NP toxicity in humans. [21] [22] [23] [24] [25] With respect to the clinical investigations, voluntary eforts from interested persons were critical. Te study questions and design for the web survey were developed by the Floxed Network and reviewed and commented upon by 2 external pharmacovigilance investigators who have extensive experience with FAERS reports. Te survey was designed with input from SONAR investigators and conducted and analyzed by the Floxed Network. Te survey results parallel results from a 2001 survey, 23 which also involved members of the Floxed Network. 23 In that study, 
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Cohen and colleagues reported that 36 of 45 persons who had received FQs and had subsequently developed possible neuorologic toxicity had reported that the neurologic dysfunction were severe, with symptoms lasting longer than 3 months in 71% of cases and more than 1 year in 58%. Onset was usually rapid, with 15 patients (33%) reporting events that began within 24 hours of initiating treatment, 26 (58%) within 72 hours, and 38 (84%) within 1 week. Almost all of the patients who reported long-term neuro-logic or psychiatric toxicities in the Cohen survey and in the present survey difer from persons who typically report serious adverse drug reactions to pharmaceutical manufacturers or the FDA in that the latter group generally reports acute events such as cardiac, severe dermatologic, or pulmonary dysfunction. Overall, web sites provide opportunities for patients to report possible serious adverse drug reactions that represent potential long-term toxicities.
Our fndings are in stark contrast to existing language in 26, 27, 28 Tree revisions, under the heading, Nervous System Disorders, describe exacerbation of myasthenia gravis, irreversible cases of peripheral neuropathy, and occurrences of pseudotumor cerebri. In 2013, based on FAERS data that identifed an increasing number of reports of irreversible peripheral neuropathy, the FDA required FQ manufacturers to revise the language in the product labels' Peripheral Nervous System sections by replacing the words "rare cases" with "may be irreversible". 26, 27, 28 Te most signifcant change in FQ labels was in 2008, when a black box warning for tendon rupture and tendinitis for all FQs was added after a patient, with the assistance of the attorney general of Illinois, fled a citizen petition with the FDA. 26, 27, 28 (Tis fling strategy was developed by SONAR, and the frst successful petition was fled in 2006). 29 Having access to revised product label toxicity sections has real-life implications: after the 2008 revision for FQ-associated tendon rupture, the percentages of levofoxacin-associated FAERS reports containing information on tendonitis or tendon rupture increased from 39.8% in 2008 to 72.4% in 2011. Te FQ safety initiative continues. In April 2013, a pharmacovigilance review from the Division of Pharmacovigilance of the FDA's Ofce of Surveillance and Epidemiology (OSE) focused on peripheral neuropathy because of consumer communications describing prolonged, disabling, neuropathy that was thought to be associated with FQs. It was the third OSE review focusing on FQ-associated neuropathy, following 2 earlier reviews in 2001 and 2003. Te review recommended that the Warnings and Precautions sections of product labels for FQs should be consistent and should indicate that irreversible neurologic toxicity may develop rapidly and be permanent, even with drug discontinuation. Te review reported that FQs afect mammalian topoisomerase II, especially in mitochondria, and that that might be the underlying pathophysiology. In 2014, SONAR submitted citizen petitions to the FDA requesting that levofoxacin's black box warning section be revised to include "possible mitochondrial toxicity" and "severe neuropsychiatric toxicities" have been observed among levofoxacin-treated persons." 30, 31 On December 18, 2014 and March 9, 2015, the FDA sent interim responses to SONAR, indicating that the mitochondrial toxicity and psychiatric toxicity petitions, respectively, raised complex issues requiring extensive review and analysis and fnal answers would be forthcoming. 32, 33 On April 23, 2015, the FDA convened a listening session with 4 persons from the Floxed Network who reported personal experiences, rationale, and summary of concerns supporting Kaur et al FIGURE 5 Local news coverage of people with suspected adverse events from fuoroquinolone use after local news agencies were informed of the fling of citizen petitions for FQ-associated NP and mitochondrial toxicity in 2013 and 2014 (November 4, 2014 to November 6, 2015).
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Original Report SONAR's request for the addition of "possible mitochondrial toxicity" to the levofoxacin label. 34 Te FDA received 96 comments on the mitochondrial toxicity request. On November 5, 2015, the FDA convened a joint meeting of its Antimicrobial Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee focusing on review of a newly identifed toxicity termed by an FDA safety reviewer as "FQ-associated disability (FQAD)." 35 At the meeting, an FDA safety reviewer described 178 FQAD reports, the senior author of this report described 54 persons with long-term FQ-associated toxicity identifed by SONAR, and 22 persons reported to the committee members their personal experiences with long-term toxicity following FQ use. 36, 37 Te FDA, SONAR, and in-person cohorts were similar with respect to age (median 46 years, range 16-83 years; median 48 years, range 13-84 years; median 46 years, range 17-70 years, respectively), percentage male (11%, 22%, 27%), onset <2 days after FQ initiation (86%, 92%, 95%), and disability of 1 month or more in all 3 cohorts. Te FDA advisory committees voted for revising FQ product labels for FDA-approved indications (21-0 for the urinary tract label change, 18-2 for the sinusitis label change, and 20-0 for the chronic obstructive pulmonary disease-acute bacterial exacerbation label change). 38 At the time of going to press, fnal responses to the citizen petitions had not been received because the FDA and FQ manufacturers were still considering actions to be taken in response to recommendations made by the advisory committees Tese safety concerns were described and covered in mainstream media ( Figure 5 ) between November 2014 (after the flings of the citizen petitions) and November 2015 (after the FDA advisory committee meeting), after the media received copies of the citizen petitions. Local television stations in 50 cities across the United States reported on the serious FQ-associated adverse drug reactions that were described in the citizen petitions. Each report included an interview with a person (or family member of a person) who had recently developed severe FQ-associated NP or in 1 instance, fatal rhabdomyolysis. In summary, severe toxicities that develop when cancer patients receive supportive care drugs such as FQs are important, yet difcult to understand, detect, and to communicate to clinicians. Our fndings support recommendations of the FDA's advisory committee that revisions of product label changes should be considered to include prominent descriptions of a newly identifed FQ-associated long-term NP toxicity, termed FQ-associated disability (FQAD) by an FDA reviewer.
